SOPHiA GENETICS , a leading cloud-native healthcare technology company advancing data-driven medicine, has announced an expanded, multi-year collaboration with AstraZeneca . The partnership will leverage SOPHiA GENETICS' advanced multimodal AI Factories to generate real-world evidence on the effectiveness, value, and clinical impact of therapies for specific forms of breast cancer.
As part of this initiative, the two companies will work towards developing a custom AI-powered predictive model to improve treatment outcomes for breast cancer patients. SOPHiA GENETICS' AI Factories, built on cutting-edge computing protocols and trained on one of the industry’s most diverse multimodal healthcare datasets, provide predictive insights into patient prognosis and therapy response.
AstraZeneca will utilize this platform to analyze comprehensive healthcare data — encompassing genomics, imaging, and clinical records — to derive AI-driven insights that can inform and enhance treatment strategies. The collaboration will also focus on generating real-world evidence across Europe and North America to identify key factors influencing treatment efficacy, address gaps in current medical knowledge, and support more informed clinical decision-making.
"This expanded partnership with AstraZeneca reflects the increasing demand for secure, scalable, and compliant AI solutions in real-world healthcare settings,” said Ross Muken, President of SOPHiA GENETICS. “Our platform is purpose-built to handle the complexity of healthcare data and this collaboration underscores our joint commitment to improving patient outcomes through federated, AI-powered analytics.”
Jorge Reis-Filho, Chief AI and Data Scientist at AstraZeneca, added, “A central pillar of our AI strategy in oncology is the integration of frontier AI technologies into clinical development. Enhancing our models with multimodal datasets — both internal and those developed through this collaboration — enables us to gain a deeper understanding of disease biology and biomarkers, ultimately helping us personalize cancer care.”
This partnership further cements SOPHiA GENETICS’ role as a trusted technology partner and highlights its mission to advance global healthcare through federated data analytics and artificial intelligence.